Review
[Myelotoxicity due to chemotherapy in oncology practice]
[Article in
French]
Affiliations
- PMID: 17274503
Item in Clipboard
Review
[Myelotoxicity due to chemotherapy in oncology practice]
[Article in
French]
Rev Prat.
.
Abstract
Myelotoxicity due to chemotherapy remains important due to its high incidence. It's one of the main toxicities due to medical treatments in oncology. Most regimens continue to be dose limited by this type of toxicity. It may concern red blood cells (anemia), white blood cells (leucopenia and neutropenia) and platelets (thrombocytopenia). The development of hematologic growth factors allows for new approaches and some modifications in the treatment of myelotoxicity.
Similar articles
-
Managing hematologic toxicities.J Support Oncol. 2004 Jan-Feb;2(1):65-79. J Support Oncol. 2004. PMID: 15330374 Review.
-
Myelotoxicity from chemotherapy.Semin Oncol. 2006 Feb;33(1):74-85. doi: 10.1053/j.seminoncol.2005.11.003. Semin Oncol. 2006. PMID: 16473646 Review.
-
[Preventing and treating hematologic complications of anticancer chemotherapy: update on hematopoietic growth factors].Bull Cancer. 2000 Jan;87(1):93-6. Bull Cancer. 2000. PMID: 10673637 Review. French. No abstract available.
-
[The strategy for chemotherapy-induced myelosuppression].Gan To Kagaku Ryoho. 2011 Nov;38(11):1777-81. Gan To Kagaku Ryoho. 2011. PMID: 22083184 Japanese.
-
Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: an observational retrospective survey.Crit Rev Oncol Hematol. 2009 Nov;72(2):170-9. doi: 10.1016/j.critrevonc.2009.03.004. Epub 2009 Apr 29. Crit Rev Oncol Hematol. 2009. PMID: 19406660